ALSO NOTED: LAB Research gains financing; BMS, AstraZeneca, Wyeth report earnings; and much more...

> Stem Cell Sciences says a new pact with the Myelin Repair Foundation will provide it with a stable supply of uniform human brain cells for their research program on multiple sclerosis. Report

> Canada's LAB Research--a non-clinical contract research organization--has raised $21.1 million in fresh financing for its expansion plans. Release

> A handful of drug makers released their earnings, and it's a mixed bag: some up, some down, some hit by one-time charges. Here's a roundup. Report

> PsychoGenics has inked a new drug discovery pact with Eli Lilly covering the evaluation of neuropsychiatric drug candidates. Report

> Chutes & Ladders: Genelabs Technologies CEO James Smith has resigned. The company chairman and CFO will run the company until a new CEO is hired on. Report

> The FDA has granted priority review status to Schering-Plough's Peginterferon Alfa-2b, an adjuvant treatment for Stage III melanoma, a rare skin cancer. Release

> If remorse is proportional to the amount you're willing to pay to absolve it, then Eli Lilly must be feeling pretty guilty about Zyprexa. Report

> Can we trust a Chinese manufacturer that not only sold contaminated cancer drugs but tried to cover up the fact? Apparently, the FDA thinks so. Report

> Good news, needle-phobes. South Korean researchers have successfully tested a new approach to delivering vaccines, applying it under the tongue rather than through a needle. Report

And Finally... See that other blue-eyed person at the next table? Go say hi, because genetics proves that you're related to a common ancestor. Release

Suggested Articles

Janssen’s BCMA-targeting CAR-T therapy eliminated tumors in 69% of patients with advanced multiple myeloma in a small phase 1 study.

In a study, BMS' CAR-T therapy banished tumors in more than half and shrank tumors in nearly three-quarters of relapsed blood cancer patients.

Novartis unveiled more data showing how its asthma combo QMF149 fared against the standard of care: a combination of the same types of drugs.